A 157.5-micron reduction in central subfield thickness is not a modest signal. That number, pulled from 108 patients at six months in ANI Pharmaceuticals’ SYNCHRONICITY trial, represents roughly a 31% collapse in retinal swelling from a baseline average of 505.7 microns — the kind of structural change that retina specialists treat as a proxy for preserved function, not just a cleaner OCT image. The trial also cleared its visual acuity co-primary endpoint, with patients gaining a mean of 3.6 ETDRS letters (p=0.0077), bringing mean BCVA from 62.5 to 65.8 letters. Both co-primary endpoints hit statistical significance in the intent-to-treat population, which matters because open-label single-arm Phase 4 designs are inherently easier to attack on methodological grounds.
The drug in question is ILUVIEN (fluocinolone acetonide intravitreal implant), which received FDA approval for chronic non-infectious uveitis affecting the posterior segment in March 2025, consolidating labeling that had previously covered the same 0.18 mg dose under a separate product. That regulatory history matters for SYNCHRONICITY’s purpose: the trial was not designed to earn approval but to generate real-world-adjacent evidence in a U.S. retina-specialist population, the exact physicians whose prescribing habits ANI needs to shift. The study population skewed older (mean age 64), majority female (65%), and heavily pretreated — 69% had prior ocular surgery — making these results harder to dismiss as cherry-picked.
The safety profile warrants attention without alarm. Among 108 patients, 29% experienced treatment-related emergent adverse events. Ocular hypertension appeared in 6% and cataract in 5%, consistent with what earlier fluocinolone acetonide trials established. The more operationally relevant number is 7%: the share requiring laser or surgical IOP-lowering intervention. Clinicians prescribing a corticosteroid implant designed to release drug for up to 36 months already expect IOP management conversations, but that intervention rate sets a benchmark for informed consent discussions as adoption broadens.
Full data head to medical conferences in Q4 2026, and that presentation moment is the one to watch closely. ANI is building a durability and safety argument to support long-cycle prescribing; the 24-month follow-up data, not yet disclosed, will determine whether the six-month structural gains hold or erode as the implant’s release curve flattens. The 24-month readout is the real commercial pivot point for ILUVIEN’s uveitis franchise.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
